Rofecoxib (Vioxx) voluntarily withdrawn from market

Merck & Co. announced Sept. 30 a voluntary worldwide withdrawal of rofecoxib (Vioxx) after a study showed patients taking the drug on a long-term basis face twice the risk of a heart attack compared with patients receiving placebo. ![Figure][1] Figure. Rofecoxib was available and promoted